New th-17 differentiation markers for rosacea and uses thereof
AssigneeGalderma Research & Development
InventorMartin Steinhoff
Life of this patent
Estimating the term…
Abstract
Methods are described for using genes crucial in TH17 differentiation, IL-12Rbeta 1/IL-23R, CCR6, BATF, AHR, STAT3 and IRF4 as new markers for rosacea. Also described, are methods of their use to diagnose rosacea, to screen inhibitors of Th17 differentiation. In particular, method are described for inhibiting at least one of these genes and using the screened inhibitors in rosacea treatment.
Claims12
A marker for rosacea, the marker comprising DNA or mRNA encoding IL-12Rbeta 1/IL-23R, CCR6, or a corresponding protein.
A marker for rosacea, the marker comprising DNA or mRNA encoding at least one transcription factor selected from the group consisting of BATF, AHR, STAT3 and IRF4, or a corresponding protein.
A method for monitoring progression or variation of rosacea, the method comprising the following steps of:
- a) taking a biological sample from an individual,
- b) analyzing a level of expression of at least one proposed marker, and/or at least one marker selected from the group consisting of IL-6, IL-17A, IL-26, IL-17F, IL-22, TNF alpha, and CCL20 in a sample and in which a variation in expression of at least one of the markers is an indicator of the progression of rosacea.
An in vitro screening method of TH17 cells differentiation inhibitors for identifying drug candidates, the method comprising the following steps:
- a) collecting at least two biological samples:
- wherein one sample mimics a rosacea lesion, and the other sample mimics a healthy condition;
- b) contacting at least one sample or a mixture of samples with one or more drug candidates to be tested;
- c) detecting expression or biological function of at least one proposed markers, and/or at least one expression marker selected from the group consisting of:
- IL-17A, IL-26, IL-17F, IL-22, TNF alpha, and CCL20 in the biological sample or mixture obtained in b);
- and
- d) selecting drug candidates that inhibit expression of IL-17A, IL-17F, IL-22, CCL20 measured in said sample or mixture obtained in b) and comparing the levels with a sample not mixed with the drug candidate.
Dependencies are inferred from the claim text.